Esophageal achalasia with mucosal damage due to enteric-coated aspirin.
Tetsuya TatsutaDaisuke ChindaTatsuya MikamiShinya SutoKazuki AkitayaShohei IgarashiKeisuke HasuiHidezumi KikuchiHiroto HiragaManabu SawayaHirotake SakurabaTadashi ShimoyamaShinsaku FukudaPublished in: Clinical journal of gastroenterology (2021)
A 76-year-old man was referred to our hospital for examination and treatment of dysphagia. He has been taking enteric-coated aspirin for myocardial infarction. Esophagogastroduodenoscopy (EGD) revealed the presence of esophageal ulcers in the distal esophagus and five to six tablets of enteric-coated aspirin. The esophageal ulcers were believed to have been caused by the retention of aspirin within the esophagus due to achalasia. We substituted enteric-coated aspirin with powdered aspirin. A follow-up EGD performed 1 month later showed improvement of esophageal mucosa. The patient was diagnosed with type I achalasia. Per-oral endoscopic myotomy was performed, and his symptoms improved after the procedure. Although a few studies have investigated the direct effect of aspirin, none of them has reported on the direct effect of aspirin on the esophagus. It might be effective to administer powdered aspirin for patients with achalasia to prevent esophageal ulcers caused by the direct effect of aspirin.
Keyphrases
- low dose
- cardiovascular events
- antiplatelet therapy
- anti inflammatory drugs
- acute coronary syndrome
- heart failure
- percutaneous coronary intervention
- healthcare
- coronary artery disease
- cardiovascular disease
- minimally invasive
- oxidative stress
- emergency department
- mass spectrometry
- physical activity
- wound healing
- molecular docking